NASDAQ:DMAC • CA25253X2077
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for DIAMEDICA THERAPEUTICS INC (DMAC).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-11-14 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-07-18 | Lake Street | Maintains | Buy -> Buy |
| 2025-07-18 | Craig-Hallum | Maintains | Buy -> Buy |
| 2025-07-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-07 | HC Wainwright & Co. | Initiate | Buy |
| 2024-08-16 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-03-21 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-03-21 | Craig-Hallum | Maintains | Buy -> Buy |
| 2023-06-22 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2022-07-07 | Lake Street | Maintains | Buy |
| 2022-07-07 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-07-07 | Craig-Hallum | Maintains | Buy |
| 2021-06-30 | Roth Capital | Maintains | Buy |
| 2021-04-08 | Oppenheimer | Initiate | Outperform |
| 2021-02-17 | Roth Capital | Initiate | Buy |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 500K | -100.00% | 3.79M | 14.304M 277.41% | 41.115M 187.44% | 121.27M 194.95% | 272.32M 124.56% | 462.86M 69.97% | 676.9M 46.24% | ||||||||||
| EBITDA YoY % growth | -2.479M -71.90% | -4.515M -82.11% | -6.746M -49.41% | -11.233M -71.54% | -11.016M -9.56% | N/A -7.45% | N/A -2.60% | -21.216M -51.95% | -26.622M -25.45% | -36.618M -37.44% | -45.594M -24.51% | -48.042M -5.37% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -2.482M -71.52% | -4.519M -82.11% | -6.761M -49.61% | -12.09M -71.47% | -12.107M -9.54% | -15.531M -7.46% | -14.069M -2.60% | -21.46M -51.90% | -26.539M -25.46% | -35.457M -32.89% | -43.7M -23.25% | -58.565M -34.01% | -63.553M -8.52% | -53.339M 16.07% | -32.281M 39.48% | 63.036M 295.27% | 211.96M 236.25% | 387.05M 82.61% | |
| Operating Margin | N/A | N/A | -1,352.20% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1,545.25% | -444.30% | -129.73% | -26.62% | 23.15% | 45.79% | 57.18% | |
| EPS YoY % growth | N/A | N/A | N/A | -0.95 -9.07% | -0.74 12.36% | -0.74 17.95% | -0.53 18.75% | -0.62 -19.23% | -0.60 3.23% | -0.70 -16.28% | -0.77 -10.53% | -0.90 -16.40% | -0.91 -1.14% | -0.68 24.72% | -0.32 53.73% | 0.84 365.58% | 2.31 175.32% | 3.90 68.82% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.18 -2.00% | -0.20 -9.55% | -0.21 -17.11% | -0.22 -30.00% | -0.23 -25.93% | -0.18 6.89% | -0.18 12.90% | -0.18 16.92% | -0.18 20.59% |
| Revenue Q2Q % growth | |||||||||
| EBITDA Q2Q % growth | -10.302M -22.94% | -10.914M -34.19% | -10.914M -36.54% | -11.934M -32.59% | -11.934M -15.84% | -12.036M -10.28% | -12.036M -10.28% | -12.036M -0.85% | -12.036M -0.85% |
| EBIT Q2Q % growth | -9.747M -15.77% | -10.342M -26.99% | -10.587M -32.22% | -11.536M -27.71% | -12.016M -23.28% | -12.036M -16.38% | -12.036M -13.69% | -12.036M -4.33% | -12.036M -0.17% |
All data in USD
11 analysts have analysed DMAC and the average price target is 15.81 USD. This implies a price increase of 128.14% is expected in the next year compared to the current price of 6.93.
DIAMEDICA THERAPEUTICS INC (DMAC) will report earnings on 2026-03-30, after the market close.
The consensus EPS estimate for the next earnings of DIAMEDICA THERAPEUTICS INC (DMAC) is -0.18 USD and the consensus revenue estimate is 0 USD.
The consensus rating for DIAMEDICA THERAPEUTICS INC (DMAC) is 81.8182 / 100 . This indicates that analysts generally have a positive outlook on the stock.